HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 433 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Children’s cancer charities team up for tomorrow’s treatments April 3, 2023 EMA Recommends Extension of Therapeutic Indications for Tisagenlecleucel May 4, 2022 EMA Recommends Granting a Marketing Authorisation for Degarelix Accord September 14, 2023 A New Study Suggests Screen Time Might Not Be The Worst... November 14, 2019 Load more HOT NEWS Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... Pride 2023: Taking on the inequalities in LGBTQ+ cancer care Doctor Wipes Away The Debt Of 200 Cancer Patients Man Who Lost Wife to Breast Cancer Wants to Donate Her...
